Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)

  1. Alegre, A.
  2. Benzo, G.
  3. Alonso, R.
  4. Martínez-López, J.
  5. Jimenez-Ubieto, A.
  6. Cuéllar, C.
  7. Askari, E.
  8. Prieto, E.
  9. Aláez, C.
  10. Aguado, B.
  11. Velasco, A.
  12. Krsnik, I.
  13. Bocanegra, A.
  14. Llorente, L.
  15. Muñoz-Linares, C.
  16. Morales, A.
  17. Giménez, E.
  18. Iglesias, R.
  19. Martínez-Chamorro, C.
  20. Alonso, A.
  21. Jiménez-Montes, C.
  22. Blanchard, M.J.
Journal:
Oncology and Therapy

ISSN: 2366-1089,  2366-1070

Year of publication: 2023

Volume: 11

Issue: 1

Pages: 83-96

Type: Article

DOI: 10.1007/S40487-022-00212-5 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus